First Tracks Biotherapeutics Inc
NASDAQ:TRAXBiotechnology
Healthcare
$44.50 -4.87%
-$0.89 today
- Market cap
- $1.87B
- Beta
- 0.00
- P/E (TTM)
- -6.1
- EPS (TTM)
- -$2.81
52W Low $14.72High $26.80
Volume 0.75M
Average 0.43M
TRAX EBITDA Margin
EBITDA as a percentage of revenue.
No reported EBITDA Margin figures are available to summarize.
EBITDA Margin history
Percent of revenue · from the income statement
No EBITDA Margin data reported for this period type.
EBITDA Margin vs competitors
How TRAX compares with its peers on the latest reported figures
TRAX Competitors Peer median
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 25.2% | +93.4 pp | +1052.7 pp | |
| LTM Mar 2026 | -843.9% | -542.0 pp | -540.2 pp | |
| FY2025 | -4915.2% | — | — | |
| LTM Sep 2026 | -7186.4% | — | — | |
TRAXFirst Tracks Biotherapeutics Inc | FY2025 | — | — | — |
| FY2025 | — | — | — | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — |
CLYMClimb Bio, Inc. | FY2025 | — | — | — |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding TRAX) | -2879.6% | -224.3 pp | +256.2 pp | |
Competitors are the stored peer set for TRAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
USD
Metric | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|
| Revenue | 0 | 0 | 0 |
| Cost of Revenue | 0 | 152.35M | 139.61M |
| Gross Profit | 0 | (152.35M) | (139.61M) |
| Gross Margin | — | — | — |
| Research & Development | 97.59M | 152.35M | 139.61M |
| Selling, General & Admin | 20.87M | 28.76M | 39.39M |
| Operating Expenses | 118.46M | 28.76M | 39.39M |
| Depreciation & Amortization | 2.38M | 2.4M | 559K |
| EBITDA | (116.09M) | (178.7M) | (178.45M) |
| EBITDA Margin | — | — | — |
| Operating Income | (118.46M) | (181.1M) | (179.01M) |
| Operating Margin | — | — | — |
| Interest Income | 12.31M | 17.38M | 0 |
| Interest Expense | 0 | 0 | 0 |
| Other Income / Expenses | 12.31M | 17.4M | 12.92M |
| Income Before Tax | (106.15M) | (163.71M) | (166.09M) |
| Pre-Tax Margin | — | — | — |
| Income Tax Expense | 0 | 0 | 0 |
| Net Income | (106.15M) | (163.71M) | (166.09M) |
| Net Margin | — | — | — |
| EPS (Basic) | (3.05) | 0.00 | 0.00 |
| EPS (Diluted) | (3.05) | 0.00 | 0.00 |
| Weighted Avg Shares | 34.75M | 0 | 0 |
| Weighted Avg Shares (Diluted) | 34.75M | 0 | 0 |
First Tracks Biotherapeutics Inc
NASDAQ:TRAX
Intrinsic Alpha fair value
Locked
Current Price
$44.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.